Compare AU
Compare IYLD vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Yield Plus ETF (IYLD) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IYLD | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 78 |
Median incremental investment | $199.00 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,654.79 | $1,274.70 |
Average age group | 26 - 35 | > 35 |
Key Summary
IYLD | CURE | |
|---|---|---|
Strategy | IYLD.AX was created on 2020-05-27 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 58.64m in AUM and 139 holdings. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of the Australian corporate bond market (excluding issuers ANZ, CBA, NAB and WBC). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | AUD CASH (2.49 %) LIBERTY FINANCIAL PTY LTD MTN RegS (1.46 %) NEWCASTLE GREATER MUTUAL GROUP LTD MTN RegS (1.44 %) | Natera Inc (2.70 %) Vertex Pharmaceuticals Inc (2.67 %) Alnylam Pharmaceuticals Inc (2.64 %) |
Top 3 industries | Other (98.80 %) Financials (1.15 %) Consumer Discretionary (1.10 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.12 % | 0.45 % |
Key Summary
IYLD | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | Bloomberg AusBond Credit and FRN Ex Big 4 Banks Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.12 % | 0.45 % |
Price | $100.29 | $42.49 |
Size | $58.792 million | $28.786 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.75 % | 4.24 % |
Market | ASX | ASX |
First listed date | 28/05/2020 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IYLD | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 78 |
Median incremental investment | $199.00 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,654.79 | $1,274.70 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
IYLD | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IYLD | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |